Abeona Therapeutics Stock Buy Hold or Sell Recommendation
| ABEO Stock | USD 6.03 0.09 1.52% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Abeona Therapeutics is 'Cautious Hold'. The recommendation algorithm takes into account all of Abeona Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Abeona Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide. In addition, we conduct extensive research on individual companies such as Abeona and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Abeona Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
Abeona |
Execute Abeona Therapeutics Buy or Sell Advice
The Abeona recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Abeona Therapeutics. Macroaxis does not own or have any residual interests in Abeona Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Abeona Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Insignificant | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Abeona Therapeutics Trading Alerts and Improvement Suggestions
| The company reported the previous year's revenue of 3.5 M. Net Loss for the year was (54.19 M) with loss before overhead, payroll, taxes, and interest of (28 M). | |
| Abeona Therapeutics currently holds about 20.1 M in cash with (37.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.38. | |
| Abeona Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 78.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Abeona shares retain Buy rating H.C. Wainwright sees approval potential for pz-cel in RDEB |
Abeona Therapeutics Returns Distribution Density
The distribution of Abeona Therapeutics' historical returns is an attempt to chart the uncertainty of Abeona Therapeutics' future price movements. The chart of the probability distribution of Abeona Therapeutics daily returns describes the distribution of returns around its average expected value. We use Abeona Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Abeona Therapeutics returns is essential to provide solid investment advice for Abeona Therapeutics.
| Mean Return | 0.14 | Value At Risk | -4.21 | Potential Upside | 3.99 | Standard Deviation | 2.54 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Abeona Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Abeona Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Abeona Therapeutics, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Abeona Therapeutics back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Walleye Trading Advisors, Llc | 2024-06-30 | 990.4 K | 683 Capital Management Llc | 2024-09-30 | 675 K | Citigroup Inc | 2024-09-30 | 616.7 K | Ikarian Capital, Llc | 2024-09-30 | 583.6 K | Geode Capital Management, Llc | 2024-09-30 | 465.3 K | Blackrock Inc | 2024-06-30 | 446.4 K | Simplify Asset Management Inc. | 2024-09-30 | 408.6 K | Newtyn Management Llc | 2024-09-30 | 380 K | Abrdn Plc | 2024-09-30 | 327 K | Suvretta Capital Management, Llc | 2024-06-30 | 3.7 M | Nantahala Capital Management, Llc | 2024-09-30 | 3.4 M |
Abeona Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 111.1M | (116.8M) | 25.3M | (24.3M) | 256K | 497.0K | |
| Free Cash Flow | (69.3M) | (36.4M) | (69.8M) | (43.6M) | (37.3M) | (35.5M) | |
| Depreciation | 8.7M | 5.6M | 4.5M | 4.6M | 3.2M | 1.8M | |
| Other Non Cash Items | 101K | 877K | (6.6M) | (5.5M) | 11.0M | 11.6M | |
| Capital Expenditures | 6.5M | 1.3M | 4.2M | 130K | 331K | 314.5K | |
| Net Income | (76.3M) | (84.2M) | (84.9M) | (39.7M) | (54.2M) | (51.5M) | |
| End Period Cash Flow | 130.4M | 13.6M | 38.8M | 14.6M | 14.8M | 20.6M | |
| Change To Inventory | (2.6M) | (1.0M) | (81K) | (16.1M) | (18.5M) | (19.4M) | |
| Change To Netincome | 7.6M | 7.3M | 42.0M | 33.1M | 38.0M | 39.9M | |
| Investments | 66.5M | (83.7M) | 66.1M | (24.0M) | 208K | 218.4K |
Abeona Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Abeona Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Abeona Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Abeona stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.05 | |
β | Beta against Dow Jones | 0.68 | |
σ | Overall volatility | 2.54 | |
Ir | Information ratio | 0.01 |
Abeona Therapeutics Volatility Alert
Abeona Therapeutics currently demonstrates below-average downside deviation. It has Information Ratio of 0.01 and Jensen Alpha of 0.05. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Abeona Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Abeona Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Abeona Therapeutics Fundamentals Vs Peers
Comparing Abeona Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Abeona Therapeutics' direct or indirect competition across all of the common fundamentals between Abeona Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Abeona Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Abeona Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Abeona Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Abeona Therapeutics to competition |
| Fundamentals | Abeona Therapeutics | Peer Average |
| Return On Equity | -1.27 | -0.31 |
| Return On Asset | -0.38 | -0.14 |
| Current Valuation | 171.63 M | 16.62 B |
| Shares Outstanding | 43.47 M | 571.82 M |
| Shares Owned By Insiders | 5.10 % | 10.09 % |
| Shares Owned By Institutions | 77.54 % | 39.21 % |
| Number Of Shares Shorted | 2.64 M | 4.71 M |
| Price To Earning | 0.11 X | 28.72 X |
| Price To Book | 5.64 X | 9.51 X |
| Price To Sales | 61.63 X | 11.42 X |
| Revenue | 3.5 M | 9.43 B |
| Gross Profit | (28 M) | 27.38 B |
| EBITDA | (50.57 M) | 3.9 B |
| Net Income | (54.19 M) | 570.98 M |
| Cash And Equivalents | 20.1 M | 2.7 B |
| Cash Per Share | 3.38 X | 5.01 X |
| Total Debt | 5.4 M | 5.32 B |
| Debt To Equity | 0.42 % | 48.70 % |
| Current Ratio | 2.21 X | 2.16 X |
| Book Value Per Share | 0.56 X | 1.93 K |
| Cash Flow From Operations | (37.01 M) | 971.22 M |
| Short Ratio | 10.79 X | 4.00 X |
| Earnings Per Share | (2.05) X | 3.12 X |
| Target Price | 16.75 | |
| Number Of Employees | 84 | 18.84 K |
| Beta | 1.51 | -0.15 |
| Market Capitalization | 258.22 M | 19.03 B |
| Total Asset | 64 M | 29.47 B |
| Retained Earnings | (749.52 M) | 9.33 B |
| Working Capital | 42.31 M | 1.48 B |
| Current Asset | 31.95 M | 9.34 B |
| Current Liabilities | 6.51 M | 7.9 B |
| Net Asset | 64 M |
Note: Disposition of 251 shares by Seshadri Vishwas of Abeona Therapeutics at 6.54 subject to Rule 16b-3 [view details]
Abeona Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Abeona . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 4906.5 | |||
| Daily Balance Of Power | 0.6429 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 6.0 | |||
| Day Typical Price | 6.01 | |||
| Price Action Indicator | 0.075 | |||
| Period Momentum Indicator | 0.09 |
About Abeona Therapeutics Buy or Sell Advice
When is the right time to buy or sell Abeona Therapeutics? Buying financial instruments such as Abeona Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Abeona Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Large Value Funds Thematic Idea Now
Large Value Funds
Funds or Etfs that invest in the undervalued stocks of large-sized companies. The Large Value Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Value Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Abeona Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.05) | Quarterly Revenue Growth (1.00) | Return On Assets (0.38) | Return On Equity (1.27) |
The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abeona Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abeona Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.